In the present study, NVP-AUY922 pretreatment attenuated the inflammatory response caused by endotoxemia, inhibited the activation of NF-κB p65 and IκB in the heart, lung, and liver (Figures 4A,B), and reduced the expression of iNOS (Figure 4C). The gene discussed is NFKB1; the disease is serum lipopolysaccharide activity.